BNTC
Benitec Biopharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.02
−2.99%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 75.0K |
| Cost of Revenue | 481.0K | 481.0K | 396.0K | 343.0K | — |
| Gross Profit | (481.0K) | (481.0K) | (396.0K) | (343.0K) | 75.0K |
| Operating Expenses | |||||
| R&D Expense | 25.1M | 23.4M | 18.3M | 15.6M | 12.8M |
| SG&A Expense | 27.8M | 27.8M | 23.4M | 7.0M | 6.4M |
| General & Admin Expense | 27.8M | 27.8M | 23.4M | 7.0M | 6.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.2M) | (481.0K) | (396.0K) | (108.0K) | — |
| Total Operating Expenses | 50.7M | 50.7M | 41.4M | 22.5M | 19.2M |
| Cost and Expenses | 51.2M | 51.2M | 41.8M | 22.5M | 19.2M |
| Operating Income (EBIT) | (51.2M) | (51.2M) | (41.8M) | (22.5M) | (19.1M) |
| Non-Operating | |||||
| Interest Income | 3.2M | 5.6M | — | 904.0K | — |
| Interest Expense | (2.4M) | — | (3.3M) | — | 33.0K |
| Net Interest Income | 5.6M | 5.6M | 3.3M | 904.0K | (33.0K) |
| Other Non-Op Income/Expense | 5.6M | 5.6M | 3.8M | 739.0K | (481.0K) |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (45.5M) | (45.5M) | (37.9M) | (21.8M) | (19.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (45.5M) | (45.5M) | (37.9M) | (21.8M) | (19.6M) |
| Earnings from Cont. Ops | (45.5M) | (45.5M) | (37.9M) | (21.8M) | (19.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (45.5M) | (45.5M) | (37.9M) | (22.4M) | (19.6M) |
| Per Share | |||||
| Basic EPS | ($0.98) | ($0.98) | ($1.05) | ($2.68) | ($14.12) |
| Diluted EPS | ($0.98) | ($0.98) | ($1.05) | ($2.68) | ($14.12) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.05 |
| Shares | |||||
| Basic Shares Outstanding | 46.6M | 46.6M | 36.2M | 10.3M | 1.4M |
| Diluted Shares Outstanding | 46.6M | 46.6M | 36.2M | 10.3M | 1.4M |
| Profitability Metrics | |||||
| EBITDA | (50.7M) | (50.7M) | (41.4M) | (22.1M) | (18.7M) |
| D&A | 481.0K | 481.0K | 396.0K | 343.0K | 381.0K |
| EBIT | (51.2M) | (51.2M) | (41.8M) | (22.5M) | (19.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026